Compare

5-Amino-1MQ vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

5-Amino-1MQ

43 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 94% · Mixed 6% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
158
Recovery
158

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
9

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.2 to ≥ 5 mg (open-ended top bucket)

0.2–0.4 mg
1
0.4–0.6 mg
2
1–2 mg
21
5+ mg
134

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 86 days · Based on 28 repeat reporters

Tirzepatide

7 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 14% · Mixed 0% · Unfavorable overall 86%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
7
Sleep
1
Mood
1
Energy
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
3
Injection site irritation
3

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.4 to ≥ 5 mg (open-ended top bucket)

0.4–0.6 mg
1
5+ mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Sources (13)

Published sources linked on the 5-Amino-1MQ and Tirzepatide wiki pages.

  1. PubMed

    An NNMT inhibitor activates oxidative metabolism and reduces obesity in mice

    Neelakantan H, Vance V, Wang H, et al. Nat Commun. 2019

    Source
    Wiki study page →
  2. PubMed

    NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

    Heide J, Bilecz AJ, Patnaik S, et al. Nature. 2025

    Source
    Wiki study page →
  3. PubMed

    Exploring NNMT: from metabolic pathways to therapeutic targets

    Park J, Shin EJ, Kim TH, et al. Archives of pharmacal research. 2024

    Source
    Wiki study page →
  4. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  5. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  8. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  9. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  11. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  12. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  13. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →